Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeWages, Salaries and Other
Others
Ratios

Sagimet Biosciences (SGMT) EBT (2023 - 2024)

Sagimet Biosciences (SGMT) has 2 years of EBT data on record, last reported at -$16.2 million in Q4 2024.

  • For Q4 2024, EBT fell 98.74% year-over-year to -$16.2 million; the TTM value through Dec 2024 reached -$45.6 million, down 63.43%, while the annual FY2025 figure was -$51.0 million, 12.01% down from the prior year.
  • EBT reached -$16.2 million in Q4 2024 per SGMT's latest filing, down from -$14.6 million in the prior quarter.
  • Across five years, EBT topped out at -$6.4 million in Q3 2023 and bottomed at -$16.2 million in Q4 2024.